Deals this week: NnBU Holdings, Somnomed, Elos Medtech

23 February 2018 (Last Updated February 23rd, 2018 15:17)

Cyprus-based medical devices developer NnBU Holdings plans to raise €15m ($18.61m) through an initial coin offering (ICO).

Cyprus-based medical devices developer NnBU Holdings plans to raise €15m ($18.61m) through an initial coin offering (ICO).

The funds are intended to be used for the research, development and commercialisation of the company’s blockchain-based C-section medical device.

Somnomed Ltd (SomnoMed) has raised A$10.4m ($8.22m) through a rights offering of 3.45 million ordinary shares priced at A$3 ($2.37) a share.

Eligible shareholders will be able to purchase one new share for 17 existing shares, as part of the offer.

The company plans to use the funds to launch its direct-to-patient obstructive sleep apnea (OSA) model at its Renew Sleep Solutions (RSS) centres located across North America and for working capital.

Somnomed appointed TDM Asset Management Pty Ltd as the financial advisor for the transaction.

Elos Medtech AB has raised SEK104.9m ($13.13m) through a rights offering of shares.

Based in Sweden, Elos is a developer and manufacturer of dental and orthopaedic solutions.

The proceeds are intended to be used for expanding the company’s production capacity.

Sofinnova Partners SAS and Fountain Healthcare Partners Ltd have invested in Irish medical device company Mainstay Medical International plc.

“The company plans to use the funds to commercialise its G-EYE product, which is used to detect polyp in cancer-prevention colonoscopy procedures.”

Pursuant to the transaction, Mainstay Medical International raised €30.1m ($37.27) through the private placement of 2.15 million ordinary shares priced at €14 ($17.33) a share.

Mainstay Medical plans to use the funds to complete the clinical trials of its ReActiv8-B implantable neurostimulation system and submit pre-market approval (PMA) application to the US FDA.

Sofinnova is a private equity firm based in France, while Fountain Healthcare Partners is an investment company based in Ireland.

Perflow Medical Ltd has raised $12m through a venture financing round led by a syndicate, including existing, international and strategic investors.

The funds are proposed to be used to commercialise Perflow’s Stream Net device in Europe and other countries.

Part of the funds will also be used to support the development of new products based on the company’s patent-protected CEREBRAL NET technology platform.

Based in Israel, Perflow is a medical device company that develops innovative tools for neurovascular interventions.

SMART Medical Systems Ltd has raised $8m through a series B financing round led by Signet Healthcare Partners.

The company plans to use the funds to commercialise its G-EYE product, which is used to detect polyp in cancer-prevention colonoscopy procedures.

Based in Israel, SMART Medical Systems is a manufacturer of innovative gastro-intestinal endoscopy products.

Excimer Therapies Inc has signed a distribution agreement for Clarteis SAS’s Exciplex product in the US.

Exciplex is a phototherapy treatment device for skin diseases.

Both the companies involved in the transaction are medical device companies based in the US.

SenzaGen AB has signed an agreement with Eurofins BioPharma Product Testing Munich (Eurofins BPT Munich) for the worldwide distribution of its GARD sensitisation test.

Based in Sweden, SenzaGen is a medical equipment company, while Eurofins is a German contract research organisation.